Seroprevalence of hepatitis D among hepatitis B-infected patients attending the viral hepatitis treatment unit in Alexandria, Egypt: a prospective cross-sectional observational study.

IF 3.2 3区医学 Q2 INFECTIOUS DISEASES

BMC Infectious Diseases Pub Date : 2026-08-14 DOI:10.1186/s12879-026-13956-6

Amany Elyamany, Rasha Ghazala, Mohamed Aboud, Ahmed Kamal

{"title":"Seroprevalence of hepatitis D among hepatitis B-infected patients attending the viral hepatitis treatment unit in Alexandria, Egypt: a prospective cross-sectional observational study.","authors":"Amany Elyamany, Rasha Ghazala, Mohamed Aboud, Ahmed Kamal","doi":"10.1186/s12879-026-13956-6","DOIUrl":null,"url":null,"abstract":"Background: Hepatitis D virus (HDV) infection accelerates liver illness progression in hepatitis B surface antigen (HBsAg)-positive individuals, yet its prevalence in Alexandria, Egypt, is unknown.Methods: We carried out a prospective cross-sectional observational study on 158 HBsAg-positive adults attending the Alexandria University Viral Hepatitis Treatment Unit (Sept 2022-Aug 2023). All underwent clinical, laboratory, and imaging assessment, and serum total anti-HDV antibodies were detected by ELISA.Results: Anti-HDV antibodies were detected in 19.6% (31/158) of patients (95% CI, 13.4%-26.8%). HDV-positive patients were older (mean 50.9 ± 12.0 vs. 45.3 ± 11.6 years, p = 0.024), had higher ALT (median 38 vs. 32 U/L, p = 0.010) and AST (median 40 vs. 31 U/L, p = 0.009), more frequent significant fibrosis (74.2% vs. 51.2%, p = 0.021), and lower HBV DNA levels (median 0.04 vs. 0.70 × 10³ IU/mL, p = 0.017). Hepatic encephalopathy was more common across HDV-positive participants (12.9% vs. 1.6%, p = 0.014).Conclusion: Nearly one in five HBsAg-positive patients in Alexandria, Egypt, had evidence of HDV exposure, with associations suggesting more advanced liver injury. These findings support universal HDV screening among all HBsAg-positive individuals in Egypt.Clinical trial number: Not applicable.","PeriodicalId":8981,"journal":{"name":"BMC Infectious Diseases","volume":"26 1","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2026-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13483714/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12879-026-13956-6","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Hepatitis D virus (HDV) infection accelerates liver illness progression in hepatitis B surface antigen (HBsAg)-positive individuals, yet its prevalence in Alexandria, Egypt, is unknown.

Methods: We carried out a prospective cross-sectional observational study on 158 HBsAg-positive adults attending the Alexandria University Viral Hepatitis Treatment Unit (Sept 2022-Aug 2023). All underwent clinical, laboratory, and imaging assessment, and serum total anti-HDV antibodies were detected by ELISA.

Results: Anti-HDV antibodies were detected in 19.6% (31/158) of patients (95% CI, 13.4%-26.8%). HDV-positive patients were older (mean 50.9 ± 12.0 vs. 45.3 ± 11.6 years, p = 0.024), had higher ALT (median 38 vs. 32 U/L, p = 0.010) and AST (median 40 vs. 31 U/L, p = 0.009), more frequent significant fibrosis (74.2% vs. 51.2%, p = 0.021), and lower HBV DNA levels (median 0.04 vs. 0.70 × 10³ IU/mL, p = 0.017). Hepatic encephalopathy was more common across HDV-positive participants (12.9% vs. 1.6%, p = 0.014).

Conclusion: Nearly one in five HBsAg-positive patients in Alexandria, Egypt, had evidence of HDV exposure, with associations suggesting more advanced liver injury. These findings support universal HDV screening among all HBsAg-positive individuals in Egypt.

Clinical trial number: Not applicable.

查看原文本刊更多论文

在埃及亚历山大市病毒性肝炎治疗单位就诊的乙型肝炎患者中丁型肝炎的血清患病率：一项前瞻性横断面观察性研究。

背景：丁型肝炎病毒（HDV）感染加速乙型肝炎表面抗原（HBsAg）阳性个体的肝病进展，但其在埃及亚历山大市的患病率尚不清楚。方法：我们对2022年9月至2023年8月在亚历山大大学病毒性肝炎治疗中心就诊的158名hbsag阳性成人进行了一项前瞻性横断面观察研究。所有患者均接受了临床、实验室和影像学评估，并通过ELISA检测血清总抗hdv抗体。结果：19.6%（31/158）的患者检测到抗hdv抗体（95% CI, 13.4% ~ 26.8%）。HBV阳性患者年龄较大（平均50.9±12.0岁vs. 45.3±11.6岁，p = 0.024）， ALT（中位数38 vs. 32 U/L, p = 0.010）和AST（中位数40 vs. 31 U/L, p = 0.009）较高，显著纤维化发生率较高（74.2% vs. 51.2%, p = 0.021）， HBV DNA水平较低（中位数0.04 vs. 0.70 × 10³IU/mL, p = 0.017）。肝性脑病在hdv阳性参与者中更为常见（12.9%比1.6%,p = 0.014）。结论：在埃及亚历山大市，近五分之一的hbsag阳性患者有HDV暴露的证据，这表明肝损伤更严重。这些发现支持在埃及所有hbsag阳性个体中进行普遍的HDV筛查。临床试验号：不适用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BMC Infectious Diseases 医学-传染病学

CiteScore

6.50

自引率

0.00%

发文量

860

审稿时长

3.3 months

期刊介绍： BMC Infectious Diseases is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of infectious and sexually transmitted diseases in humans, as well as related molecular genetics, pathophysiology, and epidemiology.